HomeGeneticsConditionCentral precocious puberty
Back to Condition
Central precocious puberty
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Central precocious puberty

Central precocious puberty is a condition causing sexual development to begin significantly earlier than the normal age range.

Overview

Puberty typically begins between ages 8 and 13 in girls and 9 and 14 in boys. In central precocious puberty, these signs appear before age 8 in girls and age 9 in boys. Symptoms include the development of pubic and underarm hair, growth spurts, acne, and body odor. Girls may develop breasts and begin menstruation, while boys may experience growth of the penis and testes and voice deepening.

While affected children may be taller than their peers initially, they may stop growing early, potentially resulting in shorter adult stature. The condition can also cause psychological and behavioral challenges due to early development.

Causes

The most common known genetic cause is a mutation in the MKRN3 gene. Puberty is triggered when the hypothalamus releases gonadotropin-releasing hormone (GnRH). The MKRN3 protein normally acts to inhibit this release, effectively holding off puberty. Mutations in MKRN3 lead to a nonfunctional protein, allowing the hypothalamus to release GnRH prematurely.

The MKRN3 gene is subject to genomic imprinting, meaning its activity depends on which parent it was inherited from. Only the copy inherited from the father is active. Consequently, the condition is typically inherited from the father.

Inheritance

Central precocious puberty follows an autosomal dominant pattern, meaning one copy of the altered gene is sufficient to cause the disorder. In familial cases, the mutation is inherited from the father. If a father carries the mutation, he may pass it to his sons and daughters. Some individuals with the mutation may not show signs of the condition, and cases can also occur sporadically without a known family history.

Frequently Asked Questions

Key red flags include breast development or menstruation before age 8 in girls, testicular enlargement before age 9 in boys, rapid growth spurt, appearance of pubic or axillary hair, acne, or body odor occurring well before the typical age range. If any of these appear, the pediatrician should be consulted for evaluation.
The first‑line treatment is a GnRH analog (e.g., leuprolide, triptorelin) given as a depot injection. These drugs continuously stimulate GnRH receptors, causing down‑regulation and suppression of LH and follicle‑stimulating hormone (FSH), halting further sexual maturation. Treatment is usually continued until the child reaches an appropriate bone age (around 11–12 years).
Central precocious puberty (CPP) is driven by early activation of the hypothalamic‑pituitary‑gonadal axis. A basal or GnRH‑stimulated luteinizing hormone (LH) level that rises to pubertal range confirms CPP. In peripheral (gonadotropin‑independent) puberty, LH remains low despite elevated sex steroids, and imaging may reveal adrenal, gonadal, or tumor sources.
When started promptly and maintained until near‑normal puberty age, GnRH analog therapy preserves final adult height by allowing normal growth‑plate closure timing. Long‑term fertility is generally unaffected because the hypothalamic‑pituitary axis resumes normal function after discontinuation of therapy. Ongoing monitoring of growth, bone age, and hormone levels is essential.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss